Abrexa Pharmaceuticals Overview
- Year Founded
-
2011

- Status
-
Private
- Latest Deal Type
-
2ndary - Private
Abrexa Pharmaceuticals General Information
Description
Developer of novel drugs designed to treat Alzheimer's disease. The company's research capabilities are focused on developing the oral curcumin derivative J-147 which is reported to address biological aging factors such as preventing the leakage of blood from microvessels in the brain, enabling patients to improve memory, and slowing the degeneration of brain cells.
Contact Information
Corporate Office
- 1282 Upas Street
- San Diego, CA 92103
- United States
Corporate Office
- 1282 Upas Street
- San Diego, CA 92103
- United States
Abrexa Pharmaceuticals Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Secondary Transaction - Private | 01-Jun-2021 | Completed | Clinical Trials - General | |||
2. Later Stage VC (Series A) | 04-Feb-2019 | Completed | Clinical Trials - General | |||
1. Early Stage VC | 06-Sep-2011 | $501K | $501K | Completed | Clinical Trials - General |
Abrexa Pharmaceuticals Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A |
Abrexa Pharmaceuticals Patents
Abrexa Pharmaceuticals Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-11938104-B1 | Compositions and methods for prevention and treatment of coronavirus and related disorders | Active | 11-Jan-2021 | ||
US-20240277640-A1 | Compositions and methods for prevention and treatment of coronavirus and related disorders | Pending | 11-Jan-2021 | ||
CA-3190520-A1 | Compounds for prevention and treatment of hemorrhage and vasculature instability | Pending | 24-Aug-2020 | ||
JP-2023538673-A | Compounds for the prevention and treatment of bleeding and vascular instability | Pending | 24-Aug-2020 | ||
EP-4204394-A1 | Compounds for prevention and treatment of hemorrhage and vasculature instability | Pending | 24-Aug-2020 | A61K31/167 |
Abrexa Pharmaceuticals FAQs
-
When was Abrexa Pharmaceuticals founded?
Abrexa Pharmaceuticals was founded in 2011.
-
Where is Abrexa Pharmaceuticals headquartered?
Abrexa Pharmaceuticals is headquartered in San Diego, CA.
-
What industry is Abrexa Pharmaceuticals in?
Abrexa Pharmaceuticals’s primary industry is Drug Discovery.
-
Is Abrexa Pharmaceuticals a private or public company?
Abrexa Pharmaceuticals is a Private company.
-
What is Abrexa Pharmaceuticals’s current revenue?
The current revenue for Abrexa Pharmaceuticals is
. -
How much funding has Abrexa Pharmaceuticals raised over time?
Abrexa Pharmaceuticals has raised $17.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »